Published in Arch Dermatol on February 01, 1968
Keratotic papule with a collarette of skin. Indian J Dermatol (2012) 0.96
Giant acquired digital fibrokeratoma occurring on the left great toe. Ann Dermatol (2011) 0.87
Giant fibrokeratoma, a rare soft tissue tumor presenting like an accessory digit, a case report and review of literature. Int J Surg Case Rep (2015) 0.75
A G protein couples serotonin and GABAB receptors to the same channels in hippocampus. Science (1986) 3.17
PACKMOL: a package for building initial configurations for molecular dynamics simulations. J Comput Chem (2009) 3.08
Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin (1985) 2.57
Ultraviolet A and melanoma: a review. J Am Acad Dermatol (2001) 2.27
Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol (1990) 2.10
Malignant melanoma. A controlled study of possibly associated factors. Arch Dermatol (1969) 2.06
Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol (1992) 1.94
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol (2000) 1.88
Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol (1991) 1.80
5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience (1991) 1.78
Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind(TM) multispectral digital dermoscope. Melanoma Res (2000) 1.78
The clinical, neuroradiographic, and endocrinologic profile of patients with bilateral optic nerve hypoplasia. Ophthalmology (1997) 1.78
Hypomelanosis of Ito ("incontinentia pigmenti achromians"). Report of three cases and review of the literature. Arch Dermatol (1973) 1.77
Solar nevogenesis: a surrogate for predicting a rise in incidence of malignant melanoma because of ozone depletion. J Am Acad Dermatol (1993) 1.73
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Bowenoid papulosis of the genitalia. Arch Dermatol (1979) 1.62
Risk of melanoma in medium-sized congenital melanocytic nevi: a follow-up study. J Am Acad Dermatol (1998) 1.60
Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis. Pediatrics (2000) 1.56
Cutaneous horns. A clinical and histopathologic study. Acta Derm Venereol (1968) 1.55
Non-melanoma skin cancer among Caucasians in four areas of the United States. Cancer (1974) 1.55
Malignant melanoma: a review. J Dermatol Surg Oncol (1977) 1.52
The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol (1996) 1.48
The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45
Congenital nevocytic nevi and malignant melanomas. J Am Acad Dermatol (1979) 1.45
Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging. Cancer (2000) 1.44
Phorbol esters mimic some cholinergic actions in hippocampal pyramidal neurons. J Neurosci (1986) 1.40
Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS (2001) 1.40
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Multicenter retrospective study of response to interferon in chronic hepatitis B. Rev Esp Enferm Dig (2000) 1.38
Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38
Muscarinic activation of a voltage-dependent cation nonselective current in rat association cortex. J Neurosci (1996) 1.36
Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
T-type Ca(2+) channels mediate neurotransmitter release in retinal bipolar cells. Neuron (2001) 1.31
Knuckle pads, leukonychia and deafness. A dominantly inherited syndrome. N Engl J Med (1967) 1.30
Curettage-electrodesiccation treatment of basal cell carcinomas. Arch Dermatol (1977) 1.29
Neurocutaneous melanosis: clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. J Am Acad Dermatol (1996) 1.27
A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24
Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry. Br J Dermatol (2005) 1.23
RNase II removes the oligo(A) tails that destabilize the rpsO mRNA of Escherichia coli. RNA (2000) 1.21
Large congenital melanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol (1996) 1.20
Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer (1995) 1.18
Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica (1970) 1.18
Ionic mechanism of the slow afterdepolarization induced by muscarinic receptor activation in rat prefrontal cortex. J Neurophysiol (1998) 1.17
Opiate- and alpha 2-adrenoceptor-induced hyperpolarizations of locus ceruleus neurons in brain slices: reversal by cyclic adenosine 3':5'-monophosphate analogues. J Neurosci (1985) 1.17
On a dilemma of penile horns: pseudoepitheliomatous, hyperkeratotic and micaceous balanitis? J Dermatol Surg Oncol (1978) 1.16
A study of large congenital melanocytic nevi and associated malignant melanomas: review of cases in the New York University Registry and the world literature. J Am Acad Dermatol (1997) 1.15
The recurrent basal cell epithelioma. A study of 100 cases of recurrent, re-treated basal cell epitheliomas. Arch Dermatol (1971) 1.15
Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol (1995) 1.13
Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol (1984) 1.12
Recurrence rates of treated basal cell carcinomas. Part 1: Overview. J Dermatol Surg Oncol (1991) 1.12
Age and malignant melanoma: comparison of variables in different age-groups. J Am Acad Dermatol (1989) 1.11
Diagnostic accuracy in malignant melanoma. Arch Dermatol (1975) 1.09
Scalpel excision of basal cell carcinomas. Arch Dermatol (1978) 1.08
Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol (1987) 1.07
Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin (2001) 1.07
Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin. CA Cancer J Clin (1991) 1.06
Three-point checklist of dermoscopy: an open internet study. Br J Dermatol (2006) 1.04
Effect of anatomical location on prognosis in patients with clinical stage I melanoma. Arch Dermatol (1983) 1.04
Prognostic index for malignant melanoma. Cancer (1987) 1.04
The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol (1987) 1.02
Sun and malignant melanoma. J Am Acad Dermatol (1984) 1.02
Risk factors for the development of malignant melanoma--I: Review of case-control studies. J Dermatol Surg Oncol (1988) 1.02
Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol (1993) 1.02
Syndromes associated with melanocytic nevi. J Am Acad Dermatol (1993) 1.01
A prognostic model for clinical stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. Am J Surg (1981) 1.01
Influence of gender on survival in patients with stage I malignant melanoma. J Am Acad Dermatol (1992) 1.01
Cutaneous malignant melanoma: prognostic guidelines for physicians and patients. CA Cancer J Clin (1982) 1.01
A 5-HT(7) receptor-mediated depolarization in the anterodorsal thalamus. II. Involvement of the hyperpolarization-activated current I(h). J Pharmacol Exp Ther (2001) 1.00
Bowenoid papulosis of the penis. Cancer (1978) 1.00